or wait 15s
Merck, known as MSD outside of the United States and Canada, and China-based startup SciBrunch Therapeutics ha
China-based Hengrui Pharma has entered into a license agreement with Novo Nordisk for HRS-1596, a phase I-read
Japan’s Chugai Pharmaceutical and InxMed (Hong Kong) have entered into a worldwide license agreement reg
The National Centre for Engineering Biology (NCEB), hosted at the National University of Singapore (NUS),
United Immunity, a clinical stage biotechnology company, has raised a total of ¥2.2 billion in private fin
The University of Melbourne has joined the Structural Genomics Consortium (SGC) with the establishment of SGC-
HKSH Medical Group (HKSH) and United Imaging Healthcare (United Imaging) have announced the arrival of Hong Ko
AIMD Inc., a Korean medical technology company specialising in AI-powered emergency care, has announced the gl
South Korea-based LOTTE Biologics, a contract development and manufacturing (CDMO) organisation, and Alvotech,
Piramal Pharma Solutions (PPS), India-based Contract Development and Manufacturing Organization (CDMO) and par
Neurology is moving from a history of high-risk failures to a period of unprecedented therapeutic experimentation. For decades, the complexity of the brain, limited understanding of disease biology and the formidable blood-brain barrier (BBB) made central nervous system (CNS) drug development one of pharma’s toughest challenges. That equation is now beginning to shift.
Advances in neurobiology, neuroimmunology, precision medicine and drug-delivery technologies are opening new routes to diseases once considered largely untreatable. Recent approvals have introduced disease-modifying and genetically targeted therapies, while the Phase III pipeline is testing approaches aimed at Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Dravet syndrome and other neurological disorders.
Behind this momentum is a deeper change: developers are moving beyond managing symptoms towards targeting the biological mechanisms that drive disease. The question now is whether this scientific momentum can finally translate into durable clinical benefit—and make disease modification a repeatable reality in neurology.
For Feedback, please email us at: coo@mmactiv.com
ADX Brisbane 2026
Australian Dental Industry Association (ADIA)
events@adia.org.au https://www.adxbrisbane.org.au/Brisbane Convention & Exhibition Centre (BCEC)
International Conference on Drug Discovery 2026
Scisynopsis
drugdiscovery@scsconferences.com https://scisynopsisconferences.com/drug-discoverySingapore
PDA Aseptic Manufacturing Excellence Conference 2026
PDA Asia Pacific
asia-pacific@pda.org https://www.pda.org/global-event-calendar/event-detail/pda-aseptic-manufacturing-excellence-conference-2026Melbourne, Australia
